About the Pulmonary Hypertension Association
The Pulmonary Hypertension Association (PHA) is dedicated to finding ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness. The vision of PHA is to improve the lives of those affected by pulmonary hypertension. More information about PHA is available at www.phassociation.org.
About Actelion Pharmaceuticals
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2000 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)).
|SOURCE Pulmonary Hypertension Association; Tufts Medical Center; Actelion Pharmaceuticals US, Inc.|
Copyright©2009 PR Newswire.
All rights reserved